Refine by
Clinical Parameter Articles & Analysis
16 news found
In-person clinic appointments are offered only to those unable to complete remote assessments. ...
When ROS production outperforms the physiological ability to counteract the deleterious effects of these reactive species a condition known as oxidative stress (OS) occurs. Clinical research activities link OS to several chronic human diseases, such as cardiovascular diseases, cognitive decline, diabetes, premature aging and frailty. The evaluation of the RedOx balance might ...
No serious adverse events were experienced during dosing with ENA001 No clinically relevant changes in cardiovascular parameters were observed during dosing with ENA001 The study results enable further elucidation of the PK/PD profile of ENA001 "We are very pleased to have completed this important study for ENA001, further demonstrating the safety and ...
The primary objective of the trial was to evaluate the safety and tolerability of TSC administered on a more frequent dosing regimen not previously tested in a clinical trial setting. Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements in blood oxygen levels, and certain other clinical ...
ByCervoMed
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita ...
Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that Eric Klein, MD, Chairman of the Glickman Urological & Kidney Institute at Cleveland Clinic, delivered two presentations at the annual meeting of the American Urological Association regarding the ...
Gamidor provides systems, reagents and services to clinical laboratories, hospitals and academic research institutions in Israel, and represents world-leading diagnostics companies, including Roche Diagnostics. ...
"Collaborating with reputable international supply partners to provide innovative diagnostic systems to clinics, doctors and the research sector is central to our identity as a company. ...
With one drop of blood and within six minutes, the HemoScreen delivers CBC results with 20 standard CBC parameters as well as comprehensive abnormal cell flagging. The device’s patented viscoelastic focusing (VEF) facilitates highly accurate measurements and sharp image-based analysis of cell characteristics, while requiring a much lower reagent volume than standard cell ...
With one drop of blood and within six minutes, the HemoScreen delivers CBC results with 20 standard CBC parameters. “The benefits of having rapid and reliable hematological test results at the point of care have been widely demonstrated to support physicians in clinical decision making in a variety of settings, from the ICU to oncology wards and in recent ...
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. ...
With one drop of blood and within six minutes, the HemoScreen delivers lab-grade 5-part differential CBC results, with 20 standard CBC parameters. “PixCell Medical provides a unique offering to this market – an exceptionally simple, portable and small sized CBC analyser that can be utilized when rapid CBC results are needed to support clinical ...
Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations Exact Sciences Corp. today announced results from a ...
BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator. ...
” He continued, “As an investigator, I am proud to present the results of this analysis demonstrating that patients with heart failure and moderate-to-severe FMR who underwent transcatheter mitral valve repair with the Carillon device, had a favorable 5-year survival rate which was associated with changes in clinical and hemodynamic parameters during ...
All capabilities are summarized on a panel of multimodal, multi-parameter results, greatly facilitating clinical concussion assessment. ...